Higher levels of CD4+ T lymphocytes can reduce the risk of recurrence, while lower levels of CD4+, CD8+, CD3+, and CD56+ T cells in advanced tumors reduce the lymphocyte-mediated anti-tumor cellular immune response, ultimately leading to worse prognosis [51]. The gene discussed is CD8A; the disease is neoplasm.